AbbVie Inc (ABBV)vsSol Gel Technologies Ltd (SLGL)
ABBV
AbbVie Inc
$209.40
+1.78%
HEALTHCARE · Cap: $370.38B
SLGL
Sol Gel Technologies Ltd
$68.54
-13.46%
HEALTHCARE · Cap: $99.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 255468% more annual revenue ($61.16B vs $23.93M). ABBV leads profitability with a 6.9% profit margin vs -14.2%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SLGL
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1199.0%
Fair Value
$16.12
Current Price
$209.40
$193.28 premium
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Strong operational efficiency at 65.1%
Revenue surging 217.7% year-over-year
Earnings expanding 487.6% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -10.2% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : SLGL
The strongest argument for SLGL centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 217.7% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 88.3x leaves little room for execution misses.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while SLGL is a hypergrowth play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.38 — expect wider price swings.
SLGL is growing revenue faster at 217.7% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?